Cell therapy for heart disease after 15 years: Unmet expectations - PubMed (original) (raw)
Review
Cell therapy for heart disease after 15 years: Unmet expectations
Patrizia Nigro et al. Pharmacol Res. 2018 Jan.
Abstract
Over the past two decades cardiac cell therapy (CCT) has emerged as a promising new strategy to cure heart diseases at high unmet need. Thousands of patients have entered clinical trials for acute or chronic heart conditions testing different cell types, including autologous or allogeneic bone marrow (BM)-derived mononuclear or selected cells, BM- or adipose tissue-derived mesenchymal cells, or cardiac resident progenitors based on their potential ability to regenerate scarred or dysfunctional myocardium. Nowadays, the original enthusiasm surrounding the regenerative medicine field has been cushioned by a cumulative body of evidence indicating an inefficient or modest efficacy of CCT in improving cardiac function, along with the continued lack of indisputable proof for long-term prognostic benefit. In this review, we have firstly comprehensively outlined the positive and negative results of cell therapy studies in patients with acute myocardial infarction, refractory angina and chronic heart failure. Next, we have discussed cell therapy- and patient-related variables (e.g. cell intrinsic and extrinsic characteristics as well as criteria of patient selection and proposed methodologies) that might have dampened the efficacy of past cell therapy trials. Finally, we have addressed critical factors to be considered before embarking on further clinical trials.
Keywords: Cardiac disease; Cell therapy; Stem cells.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
- Stem cell therapy for cardiovascular diseases: a progressive journey.
Willerson JT. Willerson JT. Curr Opin Cardiol. 2015 May;30(3):205-12. doi: 10.1097/HCO.0000000000000156. Curr Opin Cardiol. 2015. PMID: 25695897 Review. - Cell-based therapy for heart disease: a clinically oriented perspective.
Menasche P. Menasche P. Mol Ther. 2009 May;17(5):758-66. doi: 10.1038/mt.2009.40. Epub 2009 Mar 10. Mol Ther. 2009. PMID: 19277020 Free PMC article. Review. - Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI Study.
Henry TD, Schaer GL, Traverse JH, Povsic TJ, Davidson C, Lee JS, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Patel AN, Riedel N, Junge C, Hunt A, Kereiakes DJ, White C, Harrington RA, Schatz RA, Losordo DW; ACT. Henry TD, et al. Cell Transplant. 2016;25(9):1701-1711. doi: 10.3727/096368916X691484. Epub 2016 May 4. Cell Transplant. 2016. PMID: 27151378 Clinical Trial. - Allogeneic transplantation of fetal membrane-derived mesenchymal stem cell sheets increases neovascularization and improves cardiac function after myocardial infarction in rats.
Ishikane S, Hosoda H, Yamahara K, Akitake Y, Kyoungsook J, Mishima K, Iwasaki K, Fujiwara M, Miyazato M, Kangawa K, Ikeda T. Ishikane S, et al. Transplantation. 2013 Oct 27;96(8):697-706. doi: 10.1097/TP.0b013e31829f753d. Transplantation. 2013. PMID: 23912174 - [Cardiac stem cell therapy for the treatment of chronic stable angina refractory to conventional therapy. State of the art and current clinical experience of the San Raffaele Hospital of Milan, Italy].
Godino C, Briguori C, Airoldi F, Toia P, Saolini M, Ferrari A, Cera M, Fragasso G, Imros MA, Salomoni M, Todeschini P, Samanes Gajate AM, Gianolli L, Oppizzi M, Capogrossi MC, Condorelli G, Colombo A. Godino C, et al. G Ital Cardiol (Rome). 2011 Mar;12(3):198-211. G Ital Cardiol (Rome). 2011. PMID: 21560476 Review. Italian.
Cited by
- Danhong Injection Enhances the Therapeutic Efficacy of Mesenchymal Stem Cells in Myocardial Infarction by Promoting Angiogenesis.
Chen J, Wei J, Huang Y, Ma Y, Ni J, Li M, Zhu Y, Gao X, Fan G. Chen J, et al. Front Physiol. 2018 Jul 26;9:991. doi: 10.3389/fphys.2018.00991. eCollection 2018. Front Physiol. 2018. PMID: 30093864 Free PMC article. - Son of a Lesser God: The Case of Cell Therapy for Refractory Angina.
Bassetti B, Rurali E, Gambini E, Pompilio G. Bassetti B, et al. Front Cardiovasc Med. 2021 Sep 6;8:709795. doi: 10.3389/fcvm.2021.709795. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34552966 Free PMC article. Review. - Stem cell therapy for heart failure: Medical breakthrough, or dead end?
Rheault-Henry M, White I, Grover D, Atoui R. Rheault-Henry M, et al. World J Stem Cells. 2021 Apr 26;13(4):236-259. doi: 10.4252/wjsc.v13.i4.236. World J Stem Cells. 2021. PMID: 33959217 Free PMC article. Review. - GATA-targeted compounds modulate cardiac subtype cell differentiation in dual reporter stem cell line.
Välimäki MJ, Leigh RS, Kinnunen SM, March AR, de Sande AH, Kinnunen M, Varjosalo M, Heinäniemi M, Kaynak BL, Ruskoaho H. Välimäki MJ, et al. Stem Cell Res Ther. 2021 Mar 18;12(1):190. doi: 10.1186/s13287-021-02259-z. Stem Cell Res Ther. 2021. PMID: 33736688 Free PMC article. - Therapy with Cardiomyocytes Derived from Pluripotent Cells in Chronic Chagasic Cardiomyopathy.
Brasil GV, Silva Dos Santos D, Mendonça EA, Mesquita FCP, Kasai-Brunswick TH, Cunha STD, Pimentel CF, Vasconcelos-Dos-Santos A, Mendez-Otero R, Azevedo Filho CF, Goldenberg RCDS, Campos de Carvalho AC. Brasil GV, et al. Cells. 2020 Jul 7;9(7):1629. doi: 10.3390/cells9071629. Cells. 2020. PMID: 32645832 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous